Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL308704 | 1.00 | — | — | |
| SCHEMBL31125 | 0.96 | — | — | |
| SCHEMBL8816320 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL3456337 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL2728929 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL8415297 | 0.77 | ODC1 (0.93) | — | |
| Hydrochloric Acid SCHEMBL29254115 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL1002442 | 0.77 | — | — | |
| SCHEMBL25143348 | 0.74 | — | — | |
| SCHEMBL2127510 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4694933-A1 | POLYSIALIC ACID-POLYMER CONJUGATE AND NANOPARTICLE | Aviceda Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12343350-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024215999-A1 | POLYSIALIC ACID-POLYMER CONJUGATE AND NANOPARTICLE | AVICEDA THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20230293548-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-11583540-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220054502-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3934654-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | Windtree Therapeutics, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11197869-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210252017-A1 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-4284631-A | 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| US-4235931-A | ANTIDEPRESSANTS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1980-11-25 | — | — | US | disclosed |
| EP-0009548-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-16 | — | — | EP | disclosed |
| US-4192893-A | BASED ON SEROTONINE PROTENTIATION | U.S. PHILIPS CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| EP-0007633-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-06 | — | — | EP | disclosed |
| US-4086361-A | Aminoethyl oximes having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4085225-A | Oxime ethers having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1978-04-18 | — | — | US | disclosed |
| US-4081552-A | OXIME ETHERS HAVING ANTI-DEPRESSIVE ACTIVITY | U.S. PHILIPS CORPORATION (US) | 1978-03-28 | — | — | US | disclosed |
| US-4081551-A | OXIME ETHERS HAVING ANTI-DEPRESSIVE ACTIVITY | U.S. PHILIPS CORPORATION (US) | 1978-03-28 | — | — | US | disclosed |
| US-4060631-A | Aminoethyl oxime ethers having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |